Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes.

ABSTRACT:

Background

Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we investigated the association between serum protein glycation products and progression of kidney disease as well as incident major adverse cardiovascular events (MACE) in type 1 diabetes.

Methods

Fructosamine, advanced glycation end products (AGEs), and methylglyoxal-modified hydro-imidazolone (MG-H1) were measured from baseline serum samples in the FinnDiane study (n = 575). Kidney disease progression was defined as steep eGFR decline (> 3 mL/min/1.73 m²/year) or progression of albuminuria (from lower to higher stage of albuminuria). MACE was defined as acute myocardial inf

SUBMITTER: Adeshara K 

PROVIDER: S-EPMC11225254 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature